Beyond the clinical protocol, what institutional and infrastructure requirements were needed to become the first center in Louisiana to offer TIL therapy?
Fortunately for Ochsner, we already had everything in place, infrastructure-wise, for TIL therapy.2 We have great melanoma surgeons––David T. Pointer, Jr, MD; and Russell E. Brown, MD––who have had TIL experience and are familiar with TIL from their prior training. We also already had a very active cellular therapy lab because we do bone marrow stem cell transplants. We have an active CAR [chimeric antigen receptor] T-cell therapy program as well. We also already had a bunch of SOPs [standard operating procedures] in place for cellular therapy because of our CAR T program, and those protocols are very similar to [those required for] TIL [therapy]. We had a lot in place already that is needed to do TIL therapy.
The main part with TIL that’s unique and most centers don’t have a ton of experience with is managing the high-dose IL-2, which is the growth factor given after TIL infusion. But with some onboarding with Iovance [Biotherapeutics], the company that [manufactures] lifileucel, and our partner, [The University of Texas] MD Anderson Cancer Center in Houston, our inpatient oncology team was very well prepared for our first patient [whom] we treated with that [therapy]. The most important thing in preparation for new centers that want to be a TIL center is to not only get all that infrastructure in place that’s needed, as far as making sure surgeons know what to do from a protocol and harvest standpoint, and making sure you have the ability to store cellular therapy products and liquid nitrogen, but to have really good SOPs and protocols to develop with Iovance regarding the initial workup, the lymphodepleting chemotherapy, the TIL harvest and infusion, and, very importantly, the management of high-dose IL-2 toxicities. That’s really all that’s needed to be a TIL center.
What else do you consider when sequencing this therapy with immunotherapy and targeted agents, such as BRAF and MEK inhibitors?
I’m typically starting all patients with metastatic unresectable melanoma on a combination of immune checkpoint inhibitors, whether they have a BRAF mutation or not. The data from the SECOMBIT [NCT02631447] and DREAMseq [NCT02224781] studies have shown that it’s best to start with immunotherapy. Up front, that’s what I’m starting with for most patients [who] don’t have a contraindication, and whether I use nivolumab [Opdivo]/ipilimumab [Yervoy] or relatlimab-rmbw and nivolumab [Opdualag] is pretty nuanced, but if a patient has progression of disease on a combination of immune checkpoint inhibitors, that’s when I start the evaluation process for TIL therapy. The FDA label does say that [patients with] BRAF [mutation] have to have exposure to BRAF and MEK inhibitors––that is required in order to get approval. So oftentimes what I’m doing is starting the workup process and the financial authorization process while a patient may be getting started on targeted therapy in the second line for BRAF-mutated melanoma, but it’s important that the initiation of TIL should be started prior to resistance of the targeted therapy in those patients due to the rapidity of progression once that happens. Oftentimes we’re starting the process for TIL therapy, starting targeted therapy, and then potentially holding it while getting the TIL process started, getting the TIL harvested, using the targeted therapy to bridge patients to get TIL infusion.
How do you ensure you find that point before progression, without intervening too soon?
It’s a very good question that has not been figured out yet. Every center is going to have a different approach. Probably wanting to be teed up for TIL is most important, because it’s that 2- to 3-month lag that patients can’t wait for. You don’t know whether a patient is going to respond for the usual [length of time], which is about 15 months to targeted therapy, or if they’re going to respond for 3 months or 3 years. I would get started early with the harvest and approval process and then utilize targeted therapy as a bridge. Now, when to pull the trigger on the actual treatment, the actual admission for the lymphodepleting chemotherapy, infusion, et cetera, that’s probably going to be patient specific, and it may be that you stay on targeted therapy until patients show signs of progression. It’s probably going to [require] a discussion of the risks and benefits with the patient at that point.
From a mechanistic standpoint, what drives the durability of responses observed with lifileucel, and how do you counsel patients on what their response means for their prognosis?
The discussion with patients is pretty similar to my discussion before starting immune checkpoint inhibitors. The goal of all T-cell–based immunotherapies, which include immune checkpoint inhibitors and TIL therapy, is to induce a memory T-cell response, and this is what provides a durable response for 5 years. It’s important for patients to know the response rates. What’s the chance of success? For TIL therapy, response rates hover around 30%, and the 5-year overall survival rate is around 20%, so it’s important for patients to know that the majority of people are not going to have those durable responses that are lasting 5 years. However, if a patient has a response, the median duration of response is over 3 years, so most of them are very [durable]. My discussion with regard to TIL therapy is similar to my discussion for any T-cell–based immunotherapy. It’s really what the chance of success is, and then when there is a response, oftentimes there’s no ceiling to how long those responses last.
Clinical trials are studying TIL therapy outside of melanoma in lung cancer and other solid tumors. Where do you see the most promising signals, and what biological features of a tumor might predict which cancer types are most likely to respond?
The usual suspects when it comes to tumor types that respond to immune checkpoint inhibitors. [So, those with] higher tumor mutation burden and cancers that are known to have T-cell infiltrates. That’s the logical next step for TIL therapy as far as different tumor types outside of melanoma. Cervical cancer and non–small cell lung cancer [NSCLC] seem to be the most promising, with response rates ranging from 20% to 40% with TIL therapy. The biggest limitation for TIL in other tumor types will be the toxicity profile, particularly [in] patients with NSCLC [who] are heavily pretreated, [as] they have more comorbidities, are usually older,…and, given their prior treatments that they’ve typically had, [are] probably going to be less likely to tolerate high doses of lymphodepleting chemotherapy and IL-2. Moving forward, that’ll be the biggest limitation. Now, there are novel TIL regimens that are very exciting that use lower doses of lymphodepleting chemotherapy, more [like] the dosing used for CAR T cells, which makes sense, and [those that] use less toxic growth factors like IL-15. That’s needed in that space to make it more tolerable. Improvements to TIL are coming, which should hopefully open it up for a lot of different cancer types.
References
- FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. FDA. February 16, 2024. Accessed April 19, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma
- Ochsner MD Anderson uses groundbreaking TIL therapy to treat advanced melanoma in adults. News release. Ochsner Health. February 23, 2026. Accessed April 19, 2026. https://news.ochsner.org/news-releases/ochsner-md-anderson-uses-groundbreaking-til-therapy-to-treat-advanced-melanoma-in-adults/